-+ 0.00%
-+ 0.00%
-+ 0.00%

Cantor Fitzgerald Maintains Overweight on Belite Bio, Raises Price Target to $270

Benzinga·08/14/2026 11:03:35
Listen to the news
Cantor Fitzgerald analyst Steve Seedhouse maintains Belite Bio (NASDAQ:BLTE) with a Overweight and raises the price target from $266 to $270.